| abstract |
Nicotine responsive neuropsychiatric disorders are treated by administering a pharmaceutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine. The pharmaceutically effective amount is an amount sufficient to ameliorate the condition. Nicotine reactivity comprising a pharmaceutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Neuropsychiatric disorder pharmaceutical composition. Preferably, the pharmaceutically effective amount is from about 0.5 mg to about 20 mg. [Selection figure] None |